Skip to the answer

Sorafenib

Sorafenib is a kinase inhibitor used to treat certain types of liver cancer, kidney cancer, and thyroid cancer.

Brand names NexavarSorafenib Tosylate
Drug class Kinase Inhibitor
Rx Form 1
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 8 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

✓No current FDA shortage listed · checked Oct 5, 2026
Sorafenib at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Sorafenib (Nexavar) is a targeted cancer medicine for advanced liver and kidney cancer and for thyroid cancer no longer helped by radioactive iodine. It blocks the signals tumors use to grow and to build their blood supply; on the market since about 2005 and available generically, it is a well-established option, though newer treatments are often tried first. It is a demanding medicine, and the side effects people notice most are hand-foot skin reaction (red, sore or blistering palms and soles), diarrhea and tiredness. Blood pressure often climbs early, so expect weekly checks for the first six weeks, and get help right away for chest pain, unusual bleeding, or yellow skin or eyes.

Clinical pearls

  • Take it on an empty stomach, one hour before or two hours after eating; a high-fat meal cuts absorption.
  • Tell any surgeon you take sorafenib; it slows wound healing and is stopped at least 10 days before planned surgery.
  • If you take warfarin, expect more frequent INR checks (a clotting blood test), since sorafenib can raise bleeding risk.
  • Both women and men need effective birth control during treatment and afterward, six months for women, three months for men.
How we write & review this content — our editorial policy →
How you get itPrescription only
Comes asTablet
Earliest FDA record2005
Companies listing it with the FDA8
FDA label last updatedAug 28, 2023
FDA’s strongest warning (boxed)None on the label

Patient information guide A plain-language walkthrough of Sorafenib, written from its FDA label.

What Sorafenib is used for

▾

Sorafenib tablets are a kinase inhibitor approved to treat the following cancers:

  • Unresectable hepatocellular carcinoma (HCC) — liver cancer that cannot be removed by surgery. Both Nexavar and generic sorafenib tablets are approved for this.
  • Advanced renal cell carcinoma (RCC) — kidney cancer that has spread or is progressing. Both Nexavar and generic sorafenib tablets are approved for this.
  • Locally recurrent or metastatic, progressive differentiated thyroid carcinoma (DTC) — thyroid cancer that has returned, spread, or progressed and is no longer responding to radioactive iodine treatment. Both Nexavar and generic sorafenib tablets are approved for this use.

How Sorafenib works

▾

Sorafenib is what's called a kinase inhibitor — it blocks multiple proteins (kinases) that cancer cells depend on to grow and survive. These include proteins involved in tumor cell signaling (like CRAF, BRAF, and RET), as well as proteins that control the growth of new blood vessels that feed tumors (like VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-β). By blocking these signals all at once, sorafenib slows tumor cell growth, cuts off blood supply to the tumor (anti-angiogenesis), and triggers cancer cell death (apoptosis).

In laboratory and animal studies, sorafenib reduced tumor growth and blood vessel formation in liver, kidney, and thyroid cancer models — providing the scientific basis for its use in all three cancer types.

Sorafenib dosage

▾

Sorafenib tablets are taken by mouth twice a day, every day, on an empty stomach — meaning at least 1 hour before eating or 2 hours after a meal. A high-fat meal can reduce absorption by about 29%, so food timing matters. Treatment continues until your cancer is no longer responding or side effects become unacceptable.

  • Take at roughly the same times each day for consistency
  • Do not adjust your own dose — if side effects arise, your prescriber will guide any changes
  • Always follow your prescriber's and pharmacist's specific instructions

Dosing details from the FDA-approved label

From the Sorafenib prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Recommended dosage (hepatocellular carcinoma, renal cell carcinoma, differentiated thyroid carcinoma)
    • 400 mg orally twice daily without food (at least 1 hour before or 2 hours after a meal) until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity
    • Take without food
  • Dose reductions for adverse reactions: Hepatocellular Carcinoma and Renal Cell Carcinoma
    • First dose reduction: 400 mg orally once daily
    • Second dose reduction: 200 mg orally once daily OR 400 every other day
    • Third dose reduction: None
  • Dose reductions for adverse reactions: Differentiated Thyroid Carcinoma
    • First dose reduction: 400 mg orally in the morning and 200 mg orally in the evening about 12 hours apart OR 200 mg orally in the morning and 400 mg orally in the evening about 12 hours apart
    • Second dose reduction: 200 mg orally twice daily
    • Third dose reduction: 200 mg orally once daily
Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION The recommended dosage is 400 mg orally twice daily without food. ( 2.1 ) 2.1 Recommended Dosage The recommended dosage of sorafenib tablets is 400 mg orally twice daily without food (at least 1 hour before or 2 hours after a meal) until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity. 2.2 Dosage Modifications for Adverse Reactions Recommended Dosage Modifications The recommended dosage modifications for adverse reactions are provided in Tables 1, 2, and 3. Table 1: Recommended Dose Reductions for Adverse Reactions Dose Reduction Hepatocellular Carcinoma and Renal Cell Carcinoma Differentiated Thyroid Carcinoma First Dose Reduction 400 mg orally once daily 400 mg orally in the morning and 200 mg orally in the evening about 12 hours apart OR 200 mg orally in the morning and 400 mg orally in the evening about 12 hours apart Second Dose Reduction 200 mg orally once daily OR 400 every other day 200 mg orally twice daily Third Dose Reduction None 200 mg orally once daily Table 2: Recommended Dosage Modifications of Sorafenib Tablets for Adverse Reactions Adverse Reaction Severity 1 Sorafenib Tablets Dosage Modification Cardiovascular Events [see Warnings and Precautions ( 5.1 )] Cardiac Ischemia and/or Infarction Grade 2 and above Permanently discontinue. Congestive Heart Failure Grade 3 Interrupt 2 until Grade 1 or less, resume at reduced dose by 1 dose level. 3 Grade 4 Permanently discontinue. Hemorrhage [see Warnings and Precautions ( 5.2 )] Grade 2 and above requiring medical intervention Permanently discontinue. Hypertension [see Warnings and Precautions ( 5.3 )] Grade 2 (symptomatic/persistent) OR Grade 2 symptomatic increase by greater than 20 mm Hg (diastolic) or greater than 140/90 mm Hg if previously within normal limits OR Grade 3 Interrupt until symptoms resolve and diastolic blood pressure less than 90 mm Hg, then resume at reduced dose by 1 dose level. 3 If needed, reduce another dose level. 3 Grade 4 Permanently discontinue. Gastrointestinal Perforation [see Warnings and Precautions ( 5.5 )] Any grade Permanently discontinue. QT Interval Prolongation [see Warnings and Precautions ( 5.9 )] Greater than 500 milliseconds OR Increase from baseline of 60 milliseconds or greater Interrupt and correct electrolyte abnormalities (magnesium, potassium, calcium).

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Sorafenib side effects

▾

The most common side effects reported in clinical trials include:

Common side effects

  • Diarrhea
  • Fatigue
  • Hand-foot skin reaction (redness, soreness, or blistering on palms and soles)
  • Rash
  • Hair loss (alopecia)
  • Nausea or decreased appetite
  • Weight loss
  • High blood pressure (hypertension)
  • Infections

When to get medical help

  • Call your doctor right away if you have chest pain, shortness of breath, or signs of a heart attack or heart failure
  • Seek immediate care for unusual or heavy bleeding from any site
  • Tell your doctor promptly if your blood pressure stays high despite medication
  • Report severe skin reactions — blistering, peeling, or raw skin — especially if widespread
  • Seek emergency care for sudden, severe stomach pain, which could signal a gastrointestinal perforation (a hole in the gut)
  • Tell your doctor about yellowing skin or eyes, dark urine, or extreme fatigue — signs of liver injury
  • Report palpitations, dizziness, or fainting, which may signal a dangerous heart rhythm (QT prolongation)
  • If you are pregnant or planning to become pregnant, contact your doctor immediately — sorafenib can harm a developing baby

Sorafenib warnings and precautions

▾
  • Heart risks: Sorafenib can cause cardiac ischemia (reduced blood flow to the heart), heart attack, and heart failure. Tell your doctor immediately if you have chest pain or shortness of breath.
  • Bleeding: An increased risk of bleeding has been seen across all three cancer types. Bleeding that requires medical intervention may mean you need to stop sorafenib permanently.
  • High blood pressure: Very common, especially early in treatment. Blood pressure is monitored weekly for the first 6 weeks and regularly after that.
  • Severe skin reactions: Hand-foot skin reaction and rash are common and usually mild. Rarely, life-threatening reactions like Stevens-Johnson syndrome can occur — stop taking sorafenib and seek care immediately if your skin blisters or peels severely.
  • QT prolongation (a change in heart electrical rhythm that can cause dangerous arrhythmias): Regular heart monitoring (ECG) is needed if you're at risk. Certain heart medicines increase this risk.
  • Liver injury: Sorafenib can cause serious liver damage, including liver failure. Liver blood tests are monitored throughout treatment.
  • Wound healing: Sorafenib must be stopped at least 10 days before elective surgery and not restarted for at least 2 weeks after major surgery.
  • Embryo-fetal toxicity: Sorafenib can cause serious harm to a developing baby. Effective contraception is required during treatment and for months afterward.

Sorafenib interactions

▾

Sorafenib can interact with several medications and requires careful attention to what you take alongside it:

  • Strong CYP3A4 inducers (e.g., rifampin): These lower sorafenib levels in your blood, which could reduce how well it works against your cancer. Avoid if possible.
  • Neomycin: This antibiotic reduces sorafenib absorption. Avoid using them together.
  • Warfarin: Sorafenib may increase bleeding risk or raise INR (a measure of clotting time) when taken with this blood thinner. Regular monitoring is required.
  • QT-prolonging drugs (e.g., Class Ia and III antiarrhythmics): Combining these with sorafenib raises the risk of a dangerous heart rhythm. Avoid coadministration when possible.

Interactions listed in the FDA-approved label

From the Sorafenib prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Strong CYP3A4 inducers (e.g., rifampin): Concomitant use with rifampin, a strong CYP3A4 inducer, decreased the mean AUC of sorafenib, which may decrease the antitumor activity. Avoid concomitant use with strong CYP3A4 inducers, when possible.
  • Neomycin: Concomitant use decreased the mean AUC of sorafenib, which may decrease the antitumor activity. Avoid concomitant use with neomycin. The effects of other antibiotics on the pharmacokinetics of sorafenib have not been studied.
  • Warfarin: Concomitant use may increase the risk of bleeding or increased the INR. Monitor INR and for clinical bleeding episodes in patients taking warfarin while receiving sorafenib.
  • Drugs that prolong the QT interval: Sorafenib is associated with QTc interval prolongation. Avoid coadministration with medicinal products with a known potential to prolong QT/QTc interval.
Read the label’s full interactions text

Strong CYP3A Inducers: Avoid strong CYP3A4 inducers.(7.1) 7.1 Effect of Other Drugs on Sorafenib Tablets Strong CYP3A4 Inducers The concomitant use of sorafenib tablets with rifampin, a strong CYP3A4 inducer decreased the mean AUC of sorafenib, which may decrease the antitumor activity [see Clinical Pharmacology (12.3)]. Avoid concomitant use of sorafenib tablets with strong CYP3A4 inducers, when possible, because these drugs can decrease the systemic exposure to sorafenib. Neomycin The concomitant use of sorafenib tablets with neomycin decreased the mean AUC of sorafenib, which may decrease the antitumor activity. Avoid concomitant use of sorafenib tablets with neomycin. The effects of other antibiotics on the pharmacokinetics of sorafenib have not been studied [see Clinical Pharmacology (12.3)]. 7.2 Concomitant Use of Warfarin The concomitant use of sorafenib tablets and warfarin may increase the risk of bleeding or increased the INR. Monitor INR and for clinical bleeding episodes in patients taking warfarin while receiving sorafenib tablets [see Warnings and Precautions (5.6)]. 7.3 Drugs That Prolong the QT Interval Sorafenib tablets are associated with QTc interval prolongation. Avoid coadministration of sorafenib tablets with medicinal products with a known potential to prolong QT/QTc interval [see Warnings and Precautions (5.9), Clinical Pharmacology (12.2)]. 8.7 Hepatic Impairment No dose adjustment is necessary for patients with mild or moderate hepatic impairment. The pharmacokinetics of sorafenib have not been studied in patients with severe (Child-Pugh C) hepatic impairment [see Clinical Pharmacology (12.3)].

Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿285 supplements and herbs with documented Sorafenib interactions, ranked by severity Check Sorafenib against a supplement or herb →

Before taking Sorafenib

▾
  • Do not take sorafenib if you have a known severe allergy to it or any of its ingredients.
  • Do not take sorafenib combined with carboplatin and paclitaxel if you have squamous cell lung cancer — this combination is contraindicated and has been associated with higher mortality.
  • Tell your doctor if you are pregnant — sorafenib can harm a developing baby. Females of reproductive potential must use effective contraception during treatment and for 6 months after the last dose.
  • Males with partners who could become pregnant must use effective contraception during treatment and for 3 months after the last dose.
  • Do not breastfeed while taking sorafenib or for 2 weeks after stopping — it may pass into breast milk and harm a nursing baby.
  • Tell your doctor if you have heart disease, abnormal heart rhythms, or congenital long QT syndrome.
  • Sorafenib has not been proven safe or effective in children — it is not approved for pediatric use.
  • Older adults (65+) have been included in clinical trials with no overall difference in safety or effectiveness, but individual sensitivity may vary.
  • No dose adjustment is needed for mild to moderate kidney or liver impairment; those with severe liver impairment (Child-Pugh C) or patients on dialysis have not been fully studied.
  • If you have differentiated thyroid cancer, your thyroid hormone levels will need monthly monitoring since sorafenib can interfere with thyroid suppression therapy.

Sorafenib overdose

▾

Taking more than the prescribed amount of sorafenib is mainly associated with worsening diarrhea and skin reactions. If an overdose is suspected, sorafenib should be withheld and supportive medical care should be started right away. Contact a poison control center or emergency services immediately.

What Sorafenib does in the body

▾

Sorafenib affects the body by blocking multiple kinase signals that tumors use to grow and maintain their blood supply. In clinical studies, it was shown to slow tumor growth in liver, kidney, and thyroid cancers. A study of its effect on heart electrical activity found that sorafenib causes a small increase in the QTc interval (the heart's recharging time between beats) — though no large changes were seen at standard doses, this effect means heart rhythm monitoring is needed in certain patients.

How your body processes Sorafenib

▾

After you swallow sorafenib tablets, peak blood levels are reached in about 3 hours, and steady levels in the blood build up within 7 days of regular dosing. The drug has a half-life of roughly 25 to 48 hours, meaning it takes one to two days for your body to clear half of a dose. Sorafenib is broken down mainly by liver enzymes (CYP3A4 and UGT1A9) and is excreted mostly through the stool, with a smaller portion leaving through the urine. A high-fat meal significantly reduces how much sorafenib your body absorbs, which is why it must be taken on an empty stomach.

How to store Sorafenib

▾

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) . Store in a dry place.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

285

Supplements & herbs that interact with Sorafenib

285 supplements and herbal products have documented interactions with Sorafenib in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 5
  • Moderate · 241
  • Minor · 39
ACTIVATED CHARCOAL Major DANSHEN Major GRAPEFRUIT Major PIRACETAM Major ST. JOHN'S WORT Major ACACIA RIGIDULA Moderate ACONITE Moderate ADRAFINIL Moderate +277 more
Every supplement checked against Sorafenib — ranked by severity The full interaction hub: 5 major · 241 moderate · 39 minor · every one linked to its full report. Check Sorafenib against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Sorafenib: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Sorafenib — the kind of thing our pharmacy team would talk through with you at the counter.

What cancers does sorafenib actually treat?

▾
Sorafenib — sold as the brand Nexavar or as a generic — is approved for three specific cancers: liver cancer that can't be surgically removed (hepatocellular carcinoma), advanced kidney cancer (renal cell carcinoma), and a type of thyroid cancer called differentiated thyroid carcinoma that has spread or progressed and no longer responds to radioactive iodine. If you're not sure which one applies to you, your oncologist or prescriber can walk you through exactly why it was chosen for your situation.

Does it matter if I take sorafenib with food?

▾
Yes — it really does. You should take sorafenib on an empty stomach, at least 1 hour before eating or 2 hours after a meal. A high-fat meal can reduce how much of the medicine your body actually absorbs, which could make it less effective. A moderate-fat meal has less of an impact, but the safest habit is to keep it away from meals consistently. Try to take it at the same times each day.

What side effects are most common, and which ones should I call about right away?

▾
The most common ones are diarrhea, fatigue, a hand-foot skin reaction (painful redness or peeling on your palms and soles), rash, hair thinning, nausea, and high blood pressure. Most of these can be managed with supportive care or dose adjustments — so let your care team know if they're bothering you. Call your doctor right away or go to the ER if you have chest pain, heavy or unusual bleeding anywhere, severe stomach pain, severe blistering or peeling skin, yellowing of your skin or eyes, or feel your heart racing or fluttering. These could signal something serious.

Can I take my other medications while on sorafenib?

▾
Some medications can interfere with sorafenib in important ways. Rifampin (an antibiotic used for tuberculosis) and similar drugs can lower sorafenib levels in your blood, making it less effective. The antibiotic neomycin has a similar effect. If you take warfarin (a blood thinner), sorafenib can increase your bleeding risk, so your INR will need to be monitored more closely. Certain heart medicines can also combine with sorafenib to affect your heart rhythm. Always give your full medication list — including supplements and over-the-counter drugs — to your prescriber and pharmacist before starting.

Is sorafenib safe to take if I'm pregnant or trying to get pregnant?

▾
No — sorafenib can cause serious harm to a developing baby and should not be used during pregnancy. If you're a woman who could become pregnant, you'll need to use reliable birth control during treatment and for 6 months after your last dose. If you're a man whose partner could become pregnant, you'll need to use contraception during treatment and for 3 months after stopping. You also should not breastfeed while taking sorafenib or for 2 weeks after your last dose. If there's any chance you might be pregnant before starting, tell your doctor right away.

How will my doctor monitor me while I'm on sorafenib?

▾
Your doctor will keep a close eye on you throughout treatment. Expect regular blood pressure checks — weekly for the first 6 weeks at minimum. Liver function blood tests will be done routinely to catch any signs of liver injury early. If you have thyroid cancer, your TSH (a measure of thyroid hormone control) will be checked monthly, since sorafenib can interfere with thyroid suppression. If you're at risk for heart rhythm problems, your doctor may order electrocardiograms (ECGs) as well. These check-ins are a normal and important part of staying safe on this medication.

Is Sorafenib available over the counter?

▾
No. Sorafenib is a prescription medicine: every Sorafenib product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was Sorafenib first available?

▾
The earliest FDA record we hold for Sorafenib is from 2005: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Sorafenib was first used.

Who makes Sorafenib?

▾
8 companies currently list Sorafenib products in the FDA's NDC Directory, including Bayer HealthCare Pharmaceuticals Inc., Dr.Reddys Laboratories Inc, Golden State Medical Supply, Inc.. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Sorafenib on HelloPharmacist

📊Sorafenib supplement interactions285 checked — ranked by severity 🌿Drug & Supplement CheckerSorafenib vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Sorafenib NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Sorafenib Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Sorafenib forms and strengths (how it comes)

Sorafenib is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Tablet

By mouth
Brands Nexavar Sorafenib Tosylate
How this form is used
What it may be used for
  • Nexavar tablets are approved for unresectable hepatocellular carcinoma (liver cancer that cannot be surgically removed)
  • Nexavar tablets are approved for advanced renal cell carcinoma (kidney cancer)
  • Nexavar tablets are approved for locally recurrent or metastatic, progressive differentiated thyroid carcinoma that no longer responds to radioactive iodine
  • Sorafenib and Sorafenib Tosylate tablets share the same three approved indications: unresectable liver cancer, advanced kidney cancer, and radioactive iodine–refractory thyroid cancer
Important instructions
  • Take sorafenib tablets by mouth twice daily, on an empty stomach — at least 1 hour before or 2 hours after eating
  • Avoid high-fat meals around the time you take your dose, as they can reduce how much medicine your body absorbs
  • Continue taking as directed by your prescriber until they tell you to stop or adjust the dose
  • If side effects occur, your prescriber may reduce the dose or interrupt treatment — do not adjust the dose on your own
Available strengths 1 strength
200 mg
25 FDA-listed product records ⓘ

Sorafenib on the U.S. market: products, makers and brands

How Sorafenib appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

8 companies list 9 Sorafenib product records with the FDA, mostly as tablet; the earliest marketing or approval year on record is 2005. Brand names on the directory include Nexavar, Sorafenib Tosylate; the rest are generics.

1
Dose forms ⓘ
8
Labelers (makers, repackagers, distributors)
3
Brand names
9
FDA-listed product records ⓘ
2005
Earliest FDA record ⓘ

Also listed with the FDA, not a patient dose form: Powder (10) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

Bayer HealthCare Pharmaceuticals Inc.22%
Dr.Reddys Laboratories Inc11%
Golden State Medical Supply, Inc.11%
Mylan Pharmaceuticals Inc.11%
Teva Pharmaceuticals, Inc.11%
Torrent Pharmaceuticals Limited11%
Other makers22%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How widely Sorafenib is used (Medicaid data)

A general measure of how commonly Sorafenib is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Sorafenib is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

288
Medicaid prescriptions filled (Q1–Q4 2025)
$2.2M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Sorafenib prescribed? Of the 1,601 medications we measure, Sorafenib ranks #1,423 by Medicaid prescriptions — more than 11% of them.

Where Sorafenib ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #1,423 of 1,601
#1,418 Aspirin and Extended-R... 313 Rx #1,419 Gilteritinib 302 Rx #1,420 Crofelemer 301 Rx #1,421 Alprostadil Urogenital 298 Rx #1,422 Lumacaftor and Ivacaft... 291 Rx #1,423 Sorafenib 288 Rx #1,424 Tesamorelin Injection 287 Rx #1,425 Lopinavir and Ritonavi... 282 Rx #1,426 Methyldopa 282 Rx #1,427 Methyl Salicylate 282 Rx #1,428 Methamphetamine 281 Rx

Utilization by Sorafenib product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

sorafenib 200 MG Oral Tablet

288 Medicaid prescriptions (Q1–Q4 2025) 100% of Sorafenib prescriptions shown $2.2M gross reimbursement (before rebates) ≈ $7,486 per prescription (gross)

Summed across the 3 of 18 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 597747

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Sorafenib, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 3 of 18 listed Sorafenib NDCs with Medicaid activity.

Compare Sorafenib products

A representative set of FDA-listed product records for Sorafenib — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Strength Route Manufacturer / Labeler Category ⓘ Details
💊Tablet
200 mg Oral Bayer HealthCare Pharmaceuticals Inc. × 2 listings NDA View NDC →
200 mg Oral Dr.Reddys Laboratories Inc ANDA View NDC →
200 mg Oral Golden State Medical Supply, Inc. ANDA View NDC →
200 mg Oral Mylan Pharmaceuticals Inc. ANDA View NDC →
200 mg Oral Teva Pharmaceuticals, Inc. ANDA View NDC →
200 mg Oral Torrent Pharmaceuticals Limited ANDA View NDC →
200 mg Oral Upsher-Smith Laboratories, LLC ANDA View NDC →
200 mg Oral Yabao Pharmaceutical Co., Ltd. Beijing ANDA View NDC →

Showing 9 of 9 products — FDA National Drug Code Directory. See every product, package size and price: browse all 9 Sorafenib NDCs →

Sorafenib recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Sorafenib recalls since July 2021.

✅No Sorafenib recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Sorafenib RxCUI 495881 1 dose form · 1 strength
  1. Dose form (SCDF) Oral Tablet RxCUI 597746 In current FDA listings
    Clinical drug / strength (SCD) 200 MG RxCUI 597747

Look up RxCUI 495881 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

Sorafenib brand names

Sorafenib is sold under 2 brand names in the FDA directory — Nexavar, Sorafenib Tosylate. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Nexavar Sorafenib Tosylate

Who makes Sorafenib: manufacturers and labelers

8 companies list Sorafenib products with the FDA. By number of product records, the largest are Bayer HealthCare Pharmaceuticals Inc., Dr.Reddys Laboratories Inc, Golden State Medical Supply, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Bayer HealthCare Pharmaceuticals Inc. 2 Dr.Reddys Laboratories Inc 1 Golden State Medical Supply, Inc. 1 Mylan Pharmaceuticals Inc. 1 Teva Pharmaceuticals, Inc. 1 Torrent Pharmaceuticals Limited 1 Upsher-Smith Laboratories, LLC 1 Yabao Pharmaceutical Co., Ltd. Beijing 1

Sorafenib drug class (RxNorm)

Sorafenib belongs to the Kinase Inhibitor class.

Pharmacologic class Kinase Inhibitor
Drug family (ATC) Other protein kinase inhibitors
How it works Protein Kinase Inhibitors

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Sorafenib page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Aug 28, 2023
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Sorafenib.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Sorafenib after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
8
Finished products in the current FDA directory
9
Companies listing them (makers, repackagers, distributors)
8
FDA labeler codes behind them ⓘ
8
Linked representative label ⓘ
Bayer HealthCare Pharmaceuticals Inc.
Linked label effective
Aug 28, 2023
Composite sections available
21
Linked SPL Set ID
b50667e4-5ebc-4968-a646-d605058dbef0
Linked SPL Document ID
e597a26e-e04a-4f91-8c7c-a83243286396
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Bayer HealthCare Pharmaceuticals Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →